PPCO – Penwest Pharmaceuticals Co. – Shares in the pharmaceutical company that has agreed to sell itself to Endo Pharma Holdings are 5% higher today at $4.97. Penwest shareholders would receive $5.00 per share assuming the deal goes ahead. The deal price is twice the value shares in the company were trading at as recently as March this year and 25% above where they were a week ago. Still, a press release made by one legal company today claims an investigation of the Board of Directors is due and will consider a neglect of its fiduciary duties amongst other issues for failing to shop the outfit to potentially deeper-pocketed suitors. One option investor stepped up to ensure that a soured deal doesn’t cause any financial distress after shares have jumped. The investor scooped up 10,000 put options at the $5.00 strike expiring in December, paying just over five cents granting the privilege to sell the stock at that price. Looks like a low-cost wager in the event the Board is forced to bow to pressure and the buyer washes its hands of the company. However, such legal shenanigans can disappear as quickly as they arrive on the scene.